Francesco Facchinetti

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti et al. · Clinical Cancer Research · 2019 · 167 citations · Full text

Medicine, Oncology, Pharmacology +16

Crizotinib-Resistant <i>ROS1</i> Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for <i>ROS1</i> - and <i>ALK</i> -Rearranged Lung Cancers

Francesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo et al. · Clinical Cancer Research · 2016 · 149 citations

Medicine, Oncology, Pharmacology +17

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri et al. · European Journal of Cancer · 2020 · 147 citations · Full text

Medicine, Oncology, Pharmacology +13

Transferrin receptor targeting chimeras for membrane protein degradation

Dingpeng Zhang, Jhoely Duque-Jimenez, Francesco Facchinetti et al. · Nature · 2024 · 147 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

J.E. Berchuck, Francesco Facchinetti, Daniel DiToro et al. · Annals of Oncology · 2022 · 139 citations · Full text

Medicine, Cancer Biology, Oncology +17